Overview

A Study to Evaluate the Safety/Tolerability and Pharmacokinetics of Aliskiren in Hypertensive Pediatric and Adolescent Patients 6-17 Years of Age

Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
This first open-label study in a pediatric population was designed to evaluate aliskiren safety and pharmacokinetics after single and multiple dosing in 6-17 year old children with hypertension.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Novartis